On May 13, Janssen announced that its application for approval of the next-generation hepatitis C virus NS3/4A protease inhibitor simeprevir (formerly TMC435) has received priority review status from the U.S. Food and Drug Administration (FDA), giving it an estimated timeline of 6 months.
Sign up for our free twice-weekly e-newsletter
48th International Liver Congress (EASL 2013)
April 24-28, 2013, Amsterdam
|
20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) |
|
 |
The Liver Meeting (AASLD 2012) |
 |
11th International Congress on Drug Therapy in HIV Infection (HIV11) |
 |
52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) |
 |
XIX International AIDS Conference (AIDS 2012) |
Web Design and Development by Bread and Roses Web Design
